NO20052264D0 - Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser - Google Patents

Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser

Info

Publication number
NO20052264D0
NO20052264D0 NO20052264A NO20052264A NO20052264D0 NO 20052264 D0 NO20052264 D0 NO 20052264D0 NO 20052264 A NO20052264 A NO 20052264A NO 20052264 A NO20052264 A NO 20052264A NO 20052264 D0 NO20052264 D0 NO 20052264D0
Authority
NO
Norway
Prior art keywords
pregahalin
fibromyalgia
disorders
derivatives
treatment
Prior art date
Application number
NO20052264A
Other languages
English (en)
Other versions
NO20052264L (no
Inventor
David Juergen Wustrow
Jr Charles Price Taylor
Andrew John Thorpe
David James Dooley
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32600153&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052264(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20052264D0 publication Critical patent/NO20052264D0/no
Publication of NO20052264L publication Critical patent/NO20052264L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
NO20052264A 2002-12-13 2005-05-10 Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser NO20052264L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US48774003P 2003-07-16 2003-07-16
PCT/IB2003/005712 WO2004054566A1 (en) 2002-12-13 2003-12-03 Pregabalin derivatives for the treatment of fibromyalgia and other disorders

Publications (2)

Publication Number Publication Date
NO20052264D0 true NO20052264D0 (no) 2005-05-10
NO20052264L NO20052264L (no) 2005-09-12

Family

ID=32600153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052264A NO20052264L (no) 2002-12-13 2005-05-10 Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser

Country Status (15)

Country Link
US (1) US20090203782A1 (no)
EP (2) EP2172197A1 (no)
JP (1) JP2006513257A (no)
KR (1) KR20050085636A (no)
CN (1) CN101862317A (no)
AU (1) AU2003303040B2 (no)
BR (1) BR0317253A (no)
CA (1) CA2505788A1 (no)
MX (1) MXPA05006320A (no)
NO (1) NO20052264L (no)
NZ (1) NZ540591A (no)
PL (1) PL377520A1 (no)
RU (2) RU2353358C2 (no)
TW (1) TW200423925A (no)
WO (1) WO2004054566A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522146A (ja) * 2003-03-31 2006-09-28 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防
CN1878546A (zh) * 2003-09-12 2006-12-13 沃纳-兰伯特公司 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
EP3102194A1 (en) 2014-02-03 2016-12-14 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
CA2938571C (en) 2014-02-03 2020-12-22 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
EP3331851A1 (en) 2015-08-03 2018-06-13 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
EP0641330B1 (en) 1992-05-20 2001-10-17 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
DE69323212T2 (de) 1992-12-17 1999-05-27 Pfizer Pyrazole mit crf antagonistischer aktivität
RU2130453C1 (ru) 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CN1094757C (zh) * 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
BR9712651A (pt) 1996-10-23 1999-10-26 Warner Lambert Co ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
PL199794B1 (pl) 1997-10-27 2008-10-31 Warner Lambert Co Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów
ID27191A (id) 1998-07-09 2001-03-08 Warner Lambert Co Metode untuk pengobatan insomnia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
CN1196671C (zh) 1999-06-10 2005-04-13 沃尼尔·朗伯公司 单和双取代的3－丙基－γ－氨基丁酸
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6642398B2 (en) * 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6310098B1 (en) * 1999-07-22 2001-10-30 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
SK286227B6 (sk) * 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie

Also Published As

Publication number Publication date
EP2172197A1 (en) 2010-04-07
NZ540591A (en) 2008-03-28
PL377520A1 (pl) 2006-02-06
CA2505788A1 (en) 2004-07-01
RU2008140653A (ru) 2010-04-20
WO2004054566A1 (en) 2004-07-01
JP2006513257A (ja) 2006-04-20
EP1572188A1 (en) 2005-09-14
AU2003303040A1 (en) 2004-07-09
AU2003303040B2 (en) 2009-04-23
CN101862317A (zh) 2010-10-20
RU2005118081A (ru) 2006-01-20
BR0317253A (pt) 2005-11-01
RU2353358C2 (ru) 2009-04-27
NO20052264L (no) 2005-09-12
US20090203782A1 (en) 2009-08-13
TW200423925A (en) 2004-11-16
KR20050085636A (ko) 2005-08-29
MXPA05006320A (es) 2005-08-26

Similar Documents

Publication Publication Date Title
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20052796D0 (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
ZA200504724B (en) Pregabalin derivatives for the treatment of fibromyalgia and other disorders
IS7699A (is) Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
NO20055832D0 (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
NO20055152D0 (no) Karbonstyrilderivater og humor stabiliserende midler for behandling av humor forstyrrelser
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20014648L (no) Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer
NO20052859D0 (no) Fremgangsmate for fremstilling av resperidon og intermediater derav
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
NO20044250L (no) Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer
NO20033498D0 (no) Fremgangsmåte for behandling og törking av trevirke

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application